ArticleInfectious agents and cancer2025
Human papillomavirus genotypes in Jeddah, Saudi Arabia: prevalence and public health implications.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHuman papillomaviruses (HPVs) are prevalent sexually transmitted infections and a leading cause of cervical and other anogenital cancers worldwide. This study aimed to determine the prevalence and genotype distribution of HPV in Pap smear samples from women attending gynecology clinics at Dr. Soliman Fakeeh Hospital in Jeddah, Saudi Arabia, between September 2022 and July 2023.
methodsThis cross-sectional study analyzed 260 samples using nested PCR and Sanger sequencing to identify HPV genotypes.
resultsThe overall HPV prevalence rate was 6.9%. (18/260, 95% CI: 3.84-10.01%). High-risk HPV (HR-HPV) genotypes 16 (33.3%), 18 (16.7%), and 58 (5.6%) were identified, along with low-risk HPV (LR-HPV) genotype 6 (33.3%). Genotypes 11 and 67 were also detected in 5.6% of cases each. Age-specific analysis revealed the highest prevalence of HPV in the 31-40 age group, at 3.5% (p = 0.04), with HPV16 being significantly more prevalent in this age group. Saudi participants exhibited a higher prevalence rate of 61.1% (11/18) than non-Saudi participants at 38.9% (7/18). Although HPV was more common in non-Saudis, this difference was not statistically significant (p = 0.39). Cytological findings showed that 88.9% of HPV-positive cases had negative cytology, underscoring the need for HPV screening beyond cytological abnormalities.
conclusionsThese findings highlight the importance of continued surveillance, targeted vaccination efforts, and improved screening programs in Saudi Arabia. Increasing awareness of HPV and enhancing vaccination rates, especially among younger age groups, could significantly reduce the burden of HPV-related diseases. Future research should focus on broader epidemiological factors and evaluate the impact of HPV vaccination programs on genotype distribution and prevalence trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.